scholarly article | Q13442814 |
P356 | DOI | 10.1038/S41409-020-01155-Z |
P698 | PubMed publication ID | 33249424 |
P50 | author | Johan Maertens | Q89490552 |
Myriam Labopin | Q89534568 | ||
Arnon Nagler | Q89534579 | ||
Gerard Socié | Q90009154 | ||
Annalisa Paviglianiti | Q96054868 | ||
Edouard Forcade | Q103045566 | ||
Anne Huynh | Q114324317 | ||
Igor W Blau | Q114426815 | ||
Claude Eric Bulabois | Q63384859 | ||
Mohamad Mohty | Q86836425 | ||
Patrice Chevallier | Q87734444 | ||
Eric Deconinck | Q87979975 | ||
Didier Blaise | Q88013295 | ||
P2093 | author name string | Patrice Ceballos | |
Pascal Turlure | |||
Bruno Lioure | |||
Gaelle Guillerm | |||
P2860 | cites work | Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil | Q88099530 |
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation | Q91179887 | ||
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial | Q93086096 | ||
Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings | Q34363323 | ||
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q35571053 | ||
Frailty models for survival data | Q36893595 | ||
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis | Q36920445 | ||
Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! | Q38179975 | ||
The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. | Q40396484 | ||
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. | Q40843566 | ||
Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network | Q42149848 | ||
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. | Q42269523 | ||
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. | Q43102402 | ||
MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings | Q43169783 | ||
Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease | Q43241161 | ||
Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors | Q43283506 | ||
Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients | Q44216325 | ||
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia | Q44237334 | ||
Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation | Q44243900 | ||
Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation | Q45001838 | ||
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation | Q45010717 | ||
Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings | Q45132133 | ||
Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD. | Q45979461 | ||
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. | Q51759367 | ||
Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. | Q52896167 | ||
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors | Q70051817 | ||
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation | Q72419264 | ||
Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests | Q77977077 | ||
Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation | Q80694725 | ||
P577 | publication date | 2020-11-28 | |
P1433 | published in | Bone Marrow Transplantation | Q4941523 |
P1476 | title | Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT |